2 not yet recruiting. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Not yet recruiting 2 |
| Phase 2 | 2 | Not yet recruiting 2 |
Follow BreakBio Corp: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Glioblastoma (GBM) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
| Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 Therapy BreakVax, Ipilimumab 2.5 mg, Pembrolizumab - Triple-Negative Breast Cancer (TNBC) | Phase 1 / Phase 2 | Not yet recruiting | BreakBio Corp | 10 | 2026-09-01 | 2026-08-19 |
Glioblastoma (1) · Neoplasm Metastasis (1) · Triple Negative Breast Neoplasms (1)
Aspirin (2) · Ipilimumab (2) · Losartan (2) · pembrolizumab (2) · Temozolomide (1)
United States (2)